165 related articles for article (PubMed ID: 2400945)
1. Biochemical modulation of 5-fluorouracil by PALA.
O'Dwyer PJ
Cancer Invest; 1990; 8(2):261-2. PubMed ID: 2400945
[No Abstract] [Full Text] [Related]
2. Sparfosate. A novel biomodulator of 5-fluorouracil.
Koshland P; Maa L; Ignoffo R
Cancer Pract; 1999; 7(4):212-6. PubMed ID: 10687588
[No Abstract] [Full Text] [Related]
3. Role of thymidine in biochemical modulation: a review.
O'Dwyer PJ; King SA; Hoth DF; Leyland-Jones B
Cancer Res; 1987 Aug; 47(15):3911-9. PubMed ID: 3300957
[TBL] [Abstract][Full Text] [Related]
4. How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.
Ragnhammar P; Blomgren H
Med Oncol; 1995 Sep; 12(3):187-201. PubMed ID: 8852401
[No Abstract] [Full Text] [Related]
5. Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity.
Kemeny NE; Schneider A; Martin DS
Cancer Invest; 1990; 8(2):263-4. PubMed ID: 2400946
[No Abstract] [Full Text] [Related]
6. Overview of N-(phosphonacetyl)-L-aspartate + fluorouracil in clinical trials.
Martin DS; Kemeny NE
Semin Oncol; 1992 Apr; 19(2 Suppl 3):228-33. PubMed ID: 1557654
[TBL] [Abstract][Full Text] [Related]
7. The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
Köhne CH; Wilke H; Schöffski P; Schmoll HJ
J Infus Chemother; 1996; 6(4):206-10. PubMed ID: 9229317
[No Abstract] [Full Text] [Related]
8. Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
Kemeny N; Conti JA; Seiter K; Niedzwiecki D; Botet J; Martin D; Costa P; Wiseberg J; McCulloch W
J Clin Oncol; 1992 May; 10(5):747-52. PubMed ID: 1569447
[TBL] [Abstract][Full Text] [Related]
9. Biochemical modulation: a modality that has come of therapeutic age.
Allegra CJ
J Clin Oncol; 1991 Oct; 9(10):1723-6. PubMed ID: 1919622
[No Abstract] [Full Text] [Related]
10. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.
Hageboutros A; Hudes GR; Greene F; LaCreta FP; Brennan J; O'Dwyer PJ
Invest New Drugs; 1997; 15(2):139-45. PubMed ID: 9220293
[TBL] [Abstract][Full Text] [Related]
11. Biomodulation of Fluorouracil in colorectal cancer.
Ardalan B; Luis R; Jaime M; Franceschi D
Cancer Invest; 1998; 16(4):237-51. PubMed ID: 9589033
[TBL] [Abstract][Full Text] [Related]
12. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.
Cao S; Rustum YM; Spector T
Cancer Res; 1994 Mar; 54(6):1507-10. PubMed ID: 8137256
[TBL] [Abstract][Full Text] [Related]
13. Introduction to 5-fluorouracil modulation.
Martin DS
Cancer Invest; 1990; 8(2):257-8. PubMed ID: 2400944
[No Abstract] [Full Text] [Related]
14. Biochemical modulation as an approach to reversal of antimetabolite resistance.
O'Dwyer PJ
Cancer Treat Res; 1994; 73():201-16. PubMed ID: 7536018
[No Abstract] [Full Text] [Related]
15. Clinical trials referral resource. Treatment of advanced colorectal cancer.
Cheson BD
Oncology (Williston Park); 1991 Apr; 5(4):61-2, 65-6, 68 passim. PubMed ID: 1831041
[No Abstract] [Full Text] [Related]
16. Metastatic colorectal cancer: advances in biochemical modulation and new drug development.
Meropol NJ; Creaven PJ; Petrelli NJ
Semin Oncol; 1995 Oct; 22(5):509-24. PubMed ID: 7570061
[No Abstract] [Full Text] [Related]
17. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
Rosvold E; Schilder R; Walczak J; DiFino SM; Flynn PJ; Banerjee TK; Heim WJ; Engstrom PF; Ozols RF; O'Dwyer PJ
Cancer Chemother Pharmacol; 1992; 29(4):305-8. PubMed ID: 1537077
[TBL] [Abstract][Full Text] [Related]
18. Modulation of fluorouracil by N-(phosphonacetyl)-L-asparate: a review.
Martin DS; Kemeny NE
Semin Oncol; 1992 Apr; 19(2 Suppl 3):49-55. PubMed ID: 1557657
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials.
Köhne-Wömpner CH; Schmoll HJ; Harstrick A; Rustum YM
Semin Oncol; 1992 Apr; 19(2 Suppl 3):105-25. PubMed ID: 1373004
[TBL] [Abstract][Full Text] [Related]
20. Biochemical modulation: application of laboratory models to the clinic.
Leyland-Jones B; O'Dwyer PJ
Cancer Treat Rep; 1986 Jan; 70(1):219-29. PubMed ID: 3510736
[No Abstract] [Full Text] [Related]
[Next] [New Search]
